Bio Sidus

CompanyAR

Bio Sidus develops one asset, approved (teriparatide in fractures). Mostly peptide acting on PTH1R; based in AR.

Assets
1
Furthest
Approved
Trials
1
Signals
0

Pipeline

1

  • teriparatide

    Recombinant parathyroid hormone receptor agonist promoting bone formation

    ApprovedPeptidePTH1Rfractureship fracture

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials1
  • Similar companies6

Updated 7 Oct 2026 · 35 sources

Intelligence